Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT

[1]  N. Kröger,et al.  Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT , 2019, Blood Cancer Journal.

[2]  A. Migliaccio.  Faculty Opinions recommendation of MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2019, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[3]  M. Labopin,et al.  Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation , 2019, British journal of haematology.

[4]  N. Kröger,et al.  Myeloablative and Reduced-intensity conditioned Allogeneic Haematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of EBMT. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. Robin,et al.  State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019 , 2019, Haematologica.

[6]  A. Tefferi.  Primary myelofibrosis. , 2008, Cancer treatment and research.

[7]  M. Griesshammer,et al.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet , 2018, Leukemia.

[8]  P. Guglielmelli,et al.  GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis , 2018, Leukemia.

[9]  A. Tefferi,et al.  Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients , 2018, Leukemia.

[10]  M. Cazzola,et al.  MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Rowe,et al.  Allogeneic stem-cell transplantation for myelofibrosis , 2017, Current opinion in hematology.

[12]  M. Heuser,et al.  Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  S. Chevret,et al.  The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  U. Pein,et al.  Ruxolitinib for Myelofibrosis Patients Relapsing after Allogeneic Hematopoietic Transplantation , 2016 .

[15]  R. Mesa,et al.  Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis , 2016, Haematologica.

[16]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[17]  N. Kröger,et al.  Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT , 2015, British journal of haematology.

[18]  N. Kröger,et al.  Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT , 2015, Bone Marrow Transplantation.

[19]  R. Latagliata,et al.  Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. , 2015, Leukemia research.

[20]  N. Kröger,et al.  Second allograft for hematologic relapse of acute leukemia after first allogeneic stem-cell transplantation from related and unrelated donors: the role of donor change. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Kröger,et al.  Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced‐intensity allografting , 2012, British journal of haematology.

[22]  M. Bernard,et al.  Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM‐TC) , 2011, British journal of haematology.

[23]  F. Passamonti,et al.  DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Tefferi,et al.  Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.

[25]  M. Cazzola,et al.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). , 2010, Blood.

[26]  R. Mesa,et al.  New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. , 2008, Blood.

[27]  M. Cazzola,et al.  The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients , 2014, Leukemia.